Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML)

This study has been completed.
Information provided by (Responsible Party):
Asterias Biotherapeutics, Inc. Identifier:
First received: July 30, 2007
Last updated: August 11, 2014
Last verified: August 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2014
  Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)